Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2017

View Archived Issues

AntriaBio selects lead oral plasma kallikrein inhibitor candidates

InMed reports preclinical results in development of INM-405 for pain

OncBioMune Pharmaceuticals preparing clinical testing of OvcaVax

Lilly and CureVac enter global immune-oncology collaboration to develop mRNA cancer vaccines

Synspira commences phase Ia study of lead candidate for cystic fibrosis

Novartis starts phase I study of NMDA receptor NAM triggering milestone payment to Cadent

NexImmune, The Leukemia & Lymphoma Society to develop immunotherapy for AML

AST-2818 demonstrates antitumoral activity against EGFR T790M mutant NSCLC

Johnson & Johnson reviews highlights of third quarter 2017

Herpes vaccine HSV-529 safe and immunogenic in phase I trial

FDA gives fast track status to Radius Health's elacestrant

AbbVie and Harpoon Therapeutics enter immuno-oncology research collaboration

Mitsubishi Tanabe Pharma's acquisition of NeuroDerm complete

EMA grants orphan drug designation to Conatus' IDN-7314 for primary sclerosing cholangitis

Otsuka submits NDA for nalmefene in Japan

FDA advisory committee recommends approval of once-weekly semaglutide for type 2 diabetes

First-in-human phase I results presented for JNJ-64041757 immunotherapy in lung cancer

Astellas announces a new collaborative research agreement with TB Alliance

FDA approves CAR T therapy Yescarta for adults with relapsed or refractory large B-cell lymphoma

Sage Therapeutics describes novel NMDA receptor modulators

New glucosylceramidase activators identified at Lysosomal Therapeutics

FDA grants priority review to sNDA for Lynparza

AstraZeneca synthesizes novel serine-protein kinase ATM inhibitors

FluGen receives a grant from DOD to test universal flu vaccine against mismatched strains

University of Texas, Immune Sensor divulge new cyclic GMP-AMP synthase inhibitors

Loxo Oncology reports results from committee assessment of larotrectinib dataset

Protalix Biotherapeutics licenses PRX-102 to Chiesi outside U.S.

Vir Biotechnology collaborates with Alnylam and Visterra to develop programs for infectious diseases

Phase II luminespib study in non-small cell lung cancer meets primary endpoint

CEBPA gene novel mutation found to cause congenital lipodystrophy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...